InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Total Non-current Assets

All assets not expected to be converted to cash within one year.

InflaRx N.V.NASDAQ: IFRX

Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Total non-current assets rises 7.6% from a year ago

Total non-current assets stood at €1.49M at the end of Q1 FY2026, up 7.6% from a year earlier and down 5.5% from the prior quarter. Over 3 fiscal years it compounded at -31.8% a year.

Context

  • Total non-current assets amounted to 3.1% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
  • Total non-current assets increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps rising in the next quarterly balance sheet after a +7.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.49M-5.5% QoQ
Last fiscal yearDec 2025
€1.58M-63.8% YoY
Year agoMar 2025
€1.39M+7.6% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year-63.8%——
3-year CAGR-31.8%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

EUR · from the balance sheet

Latest · FY2025
1.58M EUR
Year-over-year change
-63.8%
4-year CAGR
-51.9%

Total Non-current Assets vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +7.6% is the 4th highest of 9, against a peer median of -3.8%.
  • Total non-current assets amounts to 3.1% of total assets for IFRX, versus a peer median of 9.9%.
IFRX Competitors
Total Non-current Assets for IFRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
STROSutro Biopharma, Inc.Mar 2026$21.02M USD-38.2%-24.8%8.7%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$17.22M USD-19.0%-13.6%16.2%
IMAImageneBio IncMar 2026$14.68M USD+6.0%+1.2%10.7%
ATYRaTyr Pharma, Inc.Mar 2026$12.08M USD-13.6%-2.3%15.2%
KLRSKalaris Therapeutics IncMar 2026$11.73M USD+1188.9%—10.7%
STTKShattuck Labs, Inc.Mar 2026$8.37M USD-22.3%-25.6%8.2%
CNTBConnect Biopharma Holdings LimitedDec 2025$5.15M USD+19.0%-34.4%9.2%
IFRXInflaRx N.V.Mar 2026€1.49M EUR+7.6%-31.8%3.1%
CNTXContext Therapeutics Inc.Mar 2026$342.28K USD+45.9%+7.6%0.6%
Peer median (excluding IFRX) —-3.8%-13.6%9.9%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents26.25M16.27M12.77M18.38M16.02M
Short-term Investments57.16M65.54M0030.42M
Net Receivables1.28M1.43M001.43M
Inventory0011.37M6.9M0
Other Current Assets02.55M85.06M46.03M5.75M
Total Current Assets95.68M97.41M109.47M71.66M53.61M
Property, Plant & Equipment (Net)1.68M1.64M1.36M1.01M1.15M
Goodwill00000
Intangible Assets235.22K138.91K42.84K7.26K42.24K
Long-term Investments27.21M2.9M9.05M3.09M237.27K
Tax Assets00000
Other Non-current Assets336.57K308.07K283.25K247.75K151.14K
Total Non-current Assets29.46M4.99M10.74M4.36M1.58M
Total Assets125.14M102.4M120.21M76.02M55.19M
Account Payables1.69M4.99M5.1M3.41M5.4M
Short-term Debt0000256.83K
Tax Payables00000
Deferred Revenue8.3M6.21M000
Other Current Liabilities1.52M(1.96M)2.89M301.54K6.16M
Total Current Liabilities18.76M13.03M16.84M14.17M12.98M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities35.02K36.88K36.88K36.88K36.86K
Total Non-current Liabilities1.1M1.02M782.59K435.94K677.56K
Total Liabilities19.86M14.05M17.63M14.6M13.65M
Common Stock5.3M5.36M7.07M7.12M8.67M
Retained Earnings(213.98M)(243.46M)(286.13M)(332.19M)(377.67M)
Accumulated OCI30.59M36.64M47.43M51.56M48.54M
Other Stockholders Equity3.05M7.26M107.17M
Minority Interest00000
Total Equity105.28M88.35M102.58M61.42M41.54M
Total Debt1.43M1.36M1.12M805.09K897.53K
Net Debt(24.82M)(14.91M)(11.65M)(17.57M)(15.12M)

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.